SCHEMBL5456020

SCHEMBL5456020

COC(=O)COc1ccc2c(C(N)=O)c(NC(=O)C3CC3)sc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.41
FLT3 P36888 2/20 0.40
AURKA O14965 1/20 0.40
AURKB Q96GD4 1/20 0.40
DYRK1A Q13627 1/20 0.40
CDK1 P06493 1/20 0.39
MAPKAPK2 P49137 1/20 0.39
MAPK10 P53779 2/20 0.39
PRNP P04156 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
PPARG P37231 1/20 0.39
HTT P42858 1/20 0.39
NCOA2 Q15596 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460935 0.89 MAPT (0.42) MAPTFLT3AURKAAURKBDYRK1A
SCHEMBL5451020 0.89 ABL1 (0.49) MAPTFLT3AURKAAURKBMAPK1
SCHEMBL5450710 0.87 MAPK10 (0.52) MAPTFLT3AURKAAURKBDYRK1A
SCHEMBL5455868 0.85 ABL1 (0.39) MAPTFLT3AURKAAURKBDYRK1A
SCHEMBL5449196 0.85 ABL1 (0.50) MAPTFLT3AURKAAURKBDYRK1A
SCHEMBL5454161 0.84 FLT3 (0.41) MAPTFLT3AURKAAURKBDYRK1A
SCHEMBL5453194 0.84 ALDH1A1 (0.41) MAPTFLT3AURKAAURKBMAPK10
SCHEMBL5453440 0.84 GAA (0.44) MAPTTSHRMAPK1ALDH1A1MEN1
SCHEMBL5451194 0.84 POLB (0.40) MAPTFLT3AURKAAURKBDYRK1A
SCHEMBL5459817 0.83 MAPT (0.46) MAPTFLT3AURKAAURKBDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 MAPT 21/4885FLT3 3509/4885AURKA 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.